TWEET by @CellCentric
CellCentric’s first-in-class cancer drug CCS1477 inhibits twin proteins p300/CBP. This impacts the activation of certain genes important to cancer. pic.twitter.com/wSXeFKTpRv
TWEET by @CellCentric
#ASCO21 CellCentric’s CMO, Tomasz is there, virtually. CCS1477 first in class p300/CBP inhibitor to treat multiple cancer types. pic.twitter.com/9aPUN04WHn
TWEET by @CellCentric
Targeting p300/CBP. @PCF_Science PCF AR Signalling WG Webinar today, 11am ET. @AdamSharpMedOnc of @ICR_London and @Nb10Nigel of @CellCentric. pic.twitter.com/r46sZNwGXL
TWEET by @CellCentric
Our team continues to expand. Looking for experienced people: Finance, Ops, Clinical Trials Manager. Enquires please to info@cellcentric.com pic.twitter.com/8KO6HYMKOH
TWEET by @CellCentric
Delighted to continue to work with @PCR_News, understanding the patient experience on clinical trials. Always learning. pic.twitter.com/xDSxHR9tRm
TWEET by @CellCentric
New paper by Nie et al. in Nature Cell Death & Disease: new therapeutic options via p300/CBP synthetic lethality. @panhammarstrom @zhangf nature.com/articles/s4141… pic.twitter.com/2YUq2IYp5c
